Anadys Pharmaceuticals, Inc (ANDS) Announces Positive Test Results
Anadys Pharmaceuticals, Inc. (ANDS) announced preliminary data derived from two studies of the company's ANA598 drug, focused on treating the hepatitis C virus. According to the company; "Two animals chronically infected with HCV genotype 1b each received once-daily oral doses of ANA598 at 30 mg/kg for four days. A rapid viral load decline was seen in both animals. At 48 hours (24 hours after the second dose), viral load declines were 2.2 and 2.6 log10 in the individual animals. In one animal the viral load reduction was sustained throughout the remaining dosing period, while in the second animal a modest…